These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
569 related articles for article (PubMed ID: 7585559)
1. SCH 51344 inhibits ras transformation by a novel mechanism. Kumar CC; Prorock-Rogers C; Kelly J; Dong Z; Lin JJ; Armstrong L; Kung HF; Weber MJ; Afonso A Cancer Res; 1995 Nov; 55(21):5106-17. PubMed ID: 7585559 [TBL] [Abstract][Full Text] [Related]
2. SCH 51344-induced reversal of RAS-transformation is accompanied by the specific inhibition of the RAS and RAC-dependent cell morphology pathway. Walsh AB; Dhanasekaran M; Bar-Sagi D; Kumar CC Oncogene; 1997 Nov; 15(21):2553-60. PubMed ID: 9399643 [TBL] [Abstract][Full Text] [Related]
3. [Inhibition of RAS-transformation by SCH51344]. Kumar CC Gan To Kagaku Ryoho; 1997 Sep; 24(11):1503-11. PubMed ID: 9309148 [TBL] [Abstract][Full Text] [Related]
4. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways. Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018 [TBL] [Abstract][Full Text] [Related]
5. Transformation-resistant mos revertant is unable to activate MAP kinase kinase in response to v-mos or v-raf. Topol LZ; Marx M; Calothy G; Blair DG Cell Growth Differ; 1995 Jan; 6(1):27-38. PubMed ID: 7718484 [TBL] [Abstract][Full Text] [Related]
6. Downregulation of c-fos gene transcription in cells transformed by E1A and cHa-ras oncogenes: a role of sustained activation of MAP/ERK kinase cascade and of inactive chromatin structure at c-fos promoter. Kukushkin AN; Abramova MV; Svetlikova SB; Darieva ZA; Pospelova TV; Pospelov VA Oncogene; 2002 Jan; 21(5):719-30. PubMed ID: 11850800 [TBL] [Abstract][Full Text] [Related]
7. A role for the small GTPase Rac in polyomavirus middle-T antigen-mediated activation of the serum response element and in cell transformation. Urich M; Senften M; Shaw PE; Ballmer-Hofer K Oncogene; 1997 Mar; 14(10):1235-41. PubMed ID: 9121774 [TBL] [Abstract][Full Text] [Related]
8. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells. Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316 [TBL] [Abstract][Full Text] [Related]
9. An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies. He H; Hirokawa Y; Levitzki A; Maruta H Cancer J; 2000; 6(4):243-8. PubMed ID: 11038144 [TBL] [Abstract][Full Text] [Related]
10. Comparative effects of insulin on the activation of the Raf/Mos-dependent MAP kinase cascade in vitellogenic versus postvitellogenic Xenopus oocytes. Chesnel F; Bonnec G; Tardivel A; Boujard D Dev Biol; 1997 Aug; 188(1):122-33. PubMed ID: 9245517 [TBL] [Abstract][Full Text] [Related]
11. Cellular functions of TC10, a Rho family GTPase: regulation of morphology, signal transduction and cell growth. Murphy GA; Solski PA; Jillian SA; Pérez de la Ossa P; D'Eustachio P; Der CJ; Rush MG Oncogene; 1999 Jul; 18(26):3831-45. PubMed ID: 10445846 [TBL] [Abstract][Full Text] [Related]
12. Malolactomycin D, a potent inhibitor of transcription controlled by the Ras responsive element, inhibits Ras-mediated transformation activity with suppression of MMP-1 and MMP-9 in NIH3T3 cells. Futamura M; Kamiya S; Tsukamoto M; Hirano A; Monden Y; Arakawa H; Nishimura S Oncogene; 2001 Oct; 20(46):6724-30. PubMed ID: 11709707 [TBL] [Abstract][Full Text] [Related]
13. Two serum response elements mediate transcriptional repression of human smooth muscle alpha-actin promoter in ras-transformed cells. Bushel P; Kim JH; Chang W; Catino JJ; Ruley HE; Kumar CC Oncogene; 1995 Apr; 10(7):1361-70. PubMed ID: 7731687 [TBL] [Abstract][Full Text] [Related]
14. Essential role of Raf in Ras transformation and deregulation of matrix metalloproteinase expression in ovarian epithelial cells. Ulkü AS; Schäfer R; Der CJ Mol Cancer Res; 2003 Dec; 1(14):1077-88. PubMed ID: 14707291 [TBL] [Abstract][Full Text] [Related]
15. SCH 51344, an inhibitor of RAS/RAC-mediated cell morphology pathway. Kumar CC; Ohashi K; Nagata K; Walsh A; Bar-Sagi D; Mizuno K Ann N Y Acad Sci; 1999; 886():122-31. PubMed ID: 10667210 [TBL] [Abstract][Full Text] [Related]
16. Regulation of smooth muscle alpha-actin promoter in ras-transformed cells: usefulness for setting up reporter gene-based assay system for drug screening. Kumar CC; Bushel P; Mohan-Peterson S; Ramirez F Cancer Res; 1992 Dec; 52(24):6877-84. PubMed ID: 1458476 [TBL] [Abstract][Full Text] [Related]
17. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes. Amundadottir LT; Leder P Oncogene; 1998 Feb; 16(6):737-46. PubMed ID: 9488037 [TBL] [Abstract][Full Text] [Related]
18. Mutagenic analysis of functional domains of the mos proto-oncogene and identification of the sites important for MAPK activation and DNA binding. Fukasawa K; Zhou R; Matten WT; Armstrong AJ; Daar I; Oskarsson M; Sathyanarayana BK; Maclvor L; Wood TG; Vande Woude GF Oncogene; 1995 Oct; 11(8):1447-57. PubMed ID: 7478569 [TBL] [Abstract][Full Text] [Related]
19. Radicicol suppresses transformation and restores tropomyosin-2 expression in both ras- and MEK-transformed cells without inhibiting the Raf/MEK/ERK signaling cascade. Kim PN; Jonasch E; Mosterman BC; Mier JW; Janssen RA Cell Growth Differ; 2001 Nov; 12(11):543-50. PubMed ID: 11714635 [TBL] [Abstract][Full Text] [Related]
20. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Guerrero S; Casanova I; Farré L; Mazo A; Capellà G; Mangues R Cancer Res; 2000 Dec; 60(23):6750-6. PubMed ID: 11118062 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]